Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte announced a clinical trial collaboration to test petosemtamab plus Incyte's KRAS G12D inhibitor INCB161734 with standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer. Genmab will conduct the Phase 1/2 study, while Incyte co-funds the trial and supplies INCB161734.
Key figures
- Drug Name
- petosemtamab (GEN1158) + INCB161734
- Phase Of Trial
- Phase 1/2
- Indication
- first-line KRAS G12D-mutated metastatic colorectal cancer
- Kras mutation prevalence crc
- ~15% of colorectal cancer cases
- Kras mutation prevalence any crc
- ~40% of colorectal cancers have KRAS mutations
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.